Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology

NORTHVALE, N.J., May 31, 2017, ELTP, (GLOBE NEWSWIRE) Elite Pharmaceuticals, Inc. ( Elite or the “Company ) (OTCBB:ELTP) announced today the issuance of European Patent No. 1615623 titled “Abuse-Resistant Oral Dosage Forms and Method of Use Thereof” issued March 22, 2017. This patent expands the intellectual property for the Company’s opioid abuse deterrent technology. Elite now has four US patents, one European patent, and two Canadian patents issued in this area with additional patents pending in the U.S., Canada and Europe.
http://bit.ly/2sm8Qec